Emyria (ASX:EMD) has shared interim clinical results from its MDMA-assisted therapy (MDMA-AT) program for post-traumatic stress disorder (PTSD).
The company is developing and delivering new treatments for mental health and select neurological conditions.
It said that analysis of an initial cohort of eight patients with moderate to severe PTSD reported, all of whom had limited relief from standard treatments, demonstrated continued improvement in patient outcomes three months post-treatment. PCL-5 scores, a critical measure of PTSD severity, decreased by an average of 29.6 points from baseline to the three-month follow-up.
Patients also confirm a statistically significant and sustained improvement in quality of life, with ReQoL-10 (Recovering quality of life) scores increasing by an average of 23.5 points from the baseline to the three-month follow-up.
Dr Jon Laugharne, Emyria’s lead psychiatrist, said, “It’s encouraging to see that patients continue to experience meaningful improvements in PTSD symptoms and overall well-being even months after completing treatment. These sustained benefits suggest that MDMA-assisted therapy has the potential to create lasting impacts for individuals who have struggled with severe and treatment-resistant PTSD. The data reinforces what we’ve observed in our clinic—MDMA-AT is not just reducing symptoms but helping patients reclaim their lives.”